Page 62 - Haematologica Vol. 110 - January 2025

ARTICLE - IVIG prophylaxis in pediatric ALL
K.A. Thus et al.
from Pfizer, AbbVie, Takeda, Jazz, Kura, Gilead, and Daichii Sankyo; has received consulting fees from Kura Oncology, BMS, Novartis, Gilead, Incyte, and Syndax; and has been a member of data safety monitoring boards or advisory boards for Novartis, Sanofi, and Incyte. CMT has been a member of advisory boards for Alexion, Bayer and Novartis. RP has been a member of advisory boards for Jazz Pharma and Servier. MB has been a member of an advisory board for Pfizer. The other authors have no conflicts of interest to disclose.
Contributions
KAT analyzed the data and prepared the manuscript. HAGK gathered data and analyzed the data. PWS and HS gathered data. MF analyzed the data. CCB, IMS, WJET, MAV, and CMZ enrolled patients and collected data. CMT, RP, and MB de- signed the study and interpreted data. All authors reviewed, revised, and provided final approval of the manuscript.
Acknowledgments
The authors would like to thank all included patients, mem-
References
1. Loeffen EAH, Knops RRG, Boerhof J, et al. Treatment-related mortality in children with cancer: prevalence and risk factors. Eur J Cancer. 2019;121:113-122.
2. Pieters R, de Groot-Kruseman H, Van der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2591-2601.
3. Pieters R, de Groot-Kruseman H, Fiocco M, et al. Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. J Clin Oncol. 2023;41(25):4130-4142.
4. Yeoh A, Collins A, Fox K, et al. Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2017;34(1):38-42.
5. van Tilburg CM, Bierings MB, Berbers GA, et al. Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases. Pediatr Blood Cancer. 2012;58(5):701-707.
6. van Tilburg CM, van der Velden VH, Sanders EA, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition. Leuk Res. 2011;35(4):484-491.
7. Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J
bers of the DCOG ALL-11 protocol committee, research nurses and data managers in the recruiting centers and the DCOG trial office.
Funding
The study was funded by Prothya Biosolutions who sup- plied the IVIG free of charge and the costs for pharmacy, together with a fee per patient and funding for the data center, and by the Children-Cancer Free foundation (KIKA, project number 110).
Data-sharing statement
Datasets supporting the results of the completed study, containing unidentifiable data, will be made available after the publication of the final study results, within 3 months from an initial request, to researchers who pro- vide a methodologically sound proposal. The data will be provided in compliance with applicable privacy laws, data protection, and requirements for consent and an- onymization.
Pediatr. 1999;134(5):589-596.
8. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG.
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059-1063.
9. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;2008(4):CD006501.
10. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2022.
11. Holmes EA, Friedman DL, Connelly JA, Dulek DE, Zhao Z, Esbenshade AJ. Impact of IgG monitoring and IVIG supplementation on the frequency of febrile illnesses in pediatric acute lymphoblastic leukemia patients undergoing maintenance chemotherapy. J Pediatr Hematol Oncol. 2019;41(6):423-428.
12. Van Winkle P, Burchette R, Kim R, Raghunathan R, Qureshi N. Prevalence and safety of intravenous immunoglobulin administration during maintenance chemotherapy in children with acute lymphoblastic leukemia in first complete remission: a health maintenance organization perspective. Perm J. 2018;22:17-141.
13. Foster JH, Cheng WS, Nguyen NY, Krance R, Martinez C. Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant. Pediatr Blood Cancer. 2018;65(12):e27348.
Haematologica | 110 January 2025
54